Today’s dose comes a tad late, but tune in for a ‘360-degree view’ of obesity, an FDA U-turn and a double dose of HIV-related news.

— There’s an ever-expanding body of information on obesity, and IBM is planning to help digest the raw data and offer what some news reports call a ‘360-degree view’ of the disease. The company announced a new project to build better simulation models of obesity that take numerous factors into account, such as transportation, exercise and family influences. (Business Review)

— The US Food and Drug Administration isn’t always a good listener, according to some. The agency recently approved Dendreon’s prostate cancer treatment Provenge, but three years ago it decided to go against an advisory panel’s recommendation to give the same treatment a go-ahead. This previous disagreement over Provenge represents a disturbing trend, some say. (Forbes)

— They say one person’s loss is another’s gain. That holds true in the recent Indian court ruling that determined Roche’s patent on the AIDS medication Valcyte was improperly awarded three years ago and thus no longer valid. Generic drug manufacturers and local HIV patient advocates applauded the decision. (Pharmalot)

— A new computer analysis suggests that the path of immune cell maturation that helps ‘elite controllers’ keep HIV in check may also make them more prone to autoimmune disease. The findings could also provide insight into how to make HIV therapies in the future protective against multiple strains of the virus. (NatureNews)

Image by alancleaver via Flickr Creative Commons